Cancer Family
Peripheral Nervous System Neoplasm
CI-CAN-00000316Explore in graph →
Non-malignant71 active trials8 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000316Explore in graph →
Clinical trials
261 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02211768 | Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 | completed | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04811196 | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | completed | Phase 1 | 56 | University Health Network, TorontoOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT04730583 | Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT02700230 | Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery | completed | Phase 1 | 9 | Mayo ClinicOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05438290 | DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | completed | Phase 1 | 17 | Nicholas GulatiOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03326388 | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours(INSPECT) | completed | Phase 1 / Phase 2 | 14 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03009201 | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | completed | Phase 1 | 16 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT00727233 | Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00004853 | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02008877 | SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | completed | Phase 1 / Phase 2 | 20 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT01140360 | Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas(0908-09) | completed | Phase 1 / Phase 2 | 21 | Kent RobertsonOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01999270 | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | completed | Phase 1 / Phase 2 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00720174 | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | May 17, 2016 | clinicaltrials |
| NCT01076530 | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 2 | May 3, 2013 | clinicaltrials |
| NCT01031901 | Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) | completed | Phase 1 | 52 | The University of Texas Health Science Center, HoustonOTHER | 1 | Feb 27, 2012 | clinicaltrials |
| NCT00339131 | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | completed | Phase 1 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 0 | Oct 12, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 4, 2026source: clinicaltrials